Aura Biosciences, Inc. logo AURA - Aura Biosciences, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 8
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $17.50 DETAILS
HIGH: $18.00
LOW: $17.00
MEDIAN: $17.50
CONSENSUS: $17.50
UPSIDE: 135.53%

Stock News

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Erica Kratz, Ph.D., Aura's new Chief Regulatory and Quality Officer, Susan Abu-Absi, Ph.D., Aura's new Chief Operating Officer, and Julie Person, Aura's new Chief People Officer, each on September 1, 2026 (the “Grant Date”). The Inducement Awards were approved by the Compensation Committee of the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Sep 01, 2026 12:28 PM • globenewswire.com
Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval

Aura Biosciences, Inc. is focused on late-stage development of Bel-sar for early choroidal melanoma, addressing significant unmet medical needs. The Phase 3 CoMpass trial is fully enrolled, with topline data expected in 2H 2027; Phase 2 data showed 80% tumor control and strong safety. A recent C-suite overhaul and $299M capital raise position AURA to prioritize ocular oncology and streamline operations, with funding expected to last into 2029.

Aug 12, 2026 11:22 AM • seekingalpha.com
Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario

Auranova and Kenorland Announce Large Intrusion-Related Gold Discovery at the South Uchi Project, Ontario

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2026) - Auranova Resources Inc. (TSXV: AURA) ("Auranova" or the "Company") and Kenorland Minerals Ltd. ("Kenorland") are pleased to announce complete assay results from the 2026 spring (phase 3) diamond drill program at the South Uchi Project (the "Project"), located in the Red Lake District of Ontario.

Jun 17, 2026 03:00 AM • newsfilecorp.com
Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Aura Biosciences Announces Enrollment Completion in Phase 3 CoMpass Trial of Bel-sar in Early Choroidal Melanoma

Enrollment of 108 patients completed in the registration-enabling Phase 3 CoMpass trial Topline data from the 15-month primary endpoint expected in the second half of 2027 BOSTON, June 01, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced it has completed enrollment of 108 patients in the Phase 3 trial evaluating belzupacap sarotalocan (bel-sar) as a frontline treatment for patients with early choroidal melanoma. Topline data for the 15-month primary endpoint are anticipated in the second half of 2027.

Jun 01, 2026 04:00 AM • globenewswire.com
Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Aura Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

BOSTON, May 19, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA) (“Aura” or the “Company”), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that inducement equity awards (collectively, “Inducement Awards”) were granted to Natalie Holles, Aura's new Chief Executive Officer and President, on May 19, 2026 (the “Grant Date”). The Inducement Awards are consistent with the previously disclosed terms of Ms. Holles' offer letter and were approved by the Board of Directors of the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

May 19, 2026 12:50 PM • globenewswire.com
Aura Biosciences to Participate in Upcoming Investor Conferences

Aura Biosciences to Participate in Upcoming Investor Conferences

BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that members of its senior management team will participate in the following upcoming investor conferences: H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq on Tuesday, May 19, 2026.

May 12, 2026 12:01 PM • globenewswire.com
Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Aura Biosciences Reports First Quarter 2026 Financial Results and Business Highlights

Phase 3 CoMpass trial advancing toward enrollment completion, supporting 2H 2027 topline data Natalie Holles appointed Chief Executive Officer and President and member of the Board of Directors Strengthened balance sheet with oversubscribed $299 million equity financing; cash position expected to fund operations into 2H 2028 BOSTON, May 11, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today reported financial results for the first quarter ended March 31, 2026, and provided recent business highlights. “We are entering a pivotal period for Aura as we advance our Phase 3 CoMpass trial toward enrollment completion and potential registration,” said Natalie Holles, Chief Executive Officer of Aura Biosciences.

May 11, 2026 12:01 PM • globenewswire.com
AMG Reports Better than Expected First Quarter 2026 Results

AMG Reports Better than Expected First Quarter 2026 Results

Amsterdam, 6 May 2026 (Regulated Information) --- AMG Critical Materials N.V. (“AMG”, EURONEXT AMSTERDAM: “AMG”) reports first quarter 2026 adjusted EBITDA of $44 million. This was a 2% improvement compared to the $43 million in the fourth quarter of 2025 and exceeded our guidance that the first quarter 2026 would be down sequentially. This better-than-expected performance in the current quarter was mainly driven by AMG Vanadium which included the consolidation of AURA beginning January 1, 2026. Beyond circular molybdenum, AURA brought recycled tungsten into our critical materials portfolio, and the tungsten price performance helped their results. Despite anticipated lower cash generation at the beginning of the year, AMG ended the quarter with a strong balance sheet highlighted by our $403 million of total liquidity as of March 31, 2026. This figure does not include the $127 million of proceeds from the capital increase.

May 06, 2026 08:00 AM • globenewswire.com
Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

Aura Biosciences Announces Closing of $299 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

BOSTON, May 05, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the closing of its previously announced underwritten public offering. In the offering, Aura sold (i) 46,099,650 shares of common stock, which includes 6,508,650 shares sold upon exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering, and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant.

May 05, 2026 01:15 PM • globenewswire.com
Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

Aura Biosciences Announces Pricing of $260 Million Public Offering of Common Stock and Pre-funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the pricing of an underwritten public offering consisting of (i) 39,591,000 shares of its common stock and (ii) in lieu of common stock to certain investors, pre-funded warrants to purchase an aggregate of up to 3,800,000 shares of its common stock at an exercise price of $0.00001 per pre-funded warrant. In addition, Aura has granted the underwriters a 30-day option to purchase up to an additional 6,508,650 shares of its common stock on the same terms and conditions. The offering price of each share of common stock is $6.00. The offering price of each pre-funded warrant is $5.99999.

May 04, 2026 05:03 AM • globenewswire.com
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. ("Aura") (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock.

May 04, 2026 02:03 AM • globenewswire.com
Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

Aura Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (“Aura”) (Nasdaq: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced the launch of an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of common stock. In addition, Aura intends to grant the underwriters a 30-day option to purchase up to an additional fifteen percent (15%) of shares of its common stock (and shares of common stock underlying pre-funded warrants) offered in the public offering on the same terms and conditions. All of the shares of common stock and pre-funded warrants to be sold in the offering will be offered by Aura. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

May 04, 2026 02:03 AM • globenewswire.com
Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

Aura Biosciences Announces CEO Transition as Company Advances Phase 3 CoMpass Trial Toward Enrollment Completion

Natalie Holles, seasoned industry executive with significant rare disease operational and commercialization experience, appointed Chief Executive Officer and President and member of the Board of Directors Acceleration in patient screening driving Phase 3 CoMpass trial enrollment to near completion BOSTON, May 04, 2026 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies for solid tumors designed to preserve organ function, today announced that its Board of Directors has appointed Natalie Holles as Chief Executive Officer and President and member of the Board of Directors, effective April 30, 2026. Ms. Holles succeeds Elisabet de los Pinos, Ph.D.

May 04, 2026 02:01 AM • globenewswire.com

Price Targets